RT Journal Article
T1 Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.
A1 Saberi Hosnijeh, Fatemeh
A1 Kolijn, Pieter M
A1 Casabonne, Delphine
A1 Nieters, Alexandra
A1 Solans, Marta
A1 Naudin, Sabine
A1 Ferrari, Pietro
A1 Mckay, James D
A1 Weiderpass, Elisabete
A1 Perduca, Vittorio
A1 Besson, Caroline
A1 Mancini, Francesca Romana
A1 Masala, Giovanna
A1 Krogh, Vittorio
A1 Ricceri, Fulvio
A1 Huerta, Jose M
A1 Petrova, Dafina
A1 Sala, Nuria
A1 Trichopoulou, Antonia
A1 Karakatsani, Anna
A1 La Vecchia, Carlo
A1 Kaaks, Rudolf
A1 Canzian, Federico
A1 Aune, Dagfinn
A1 Boeing, Heiner
A1 Schulze, Matthias B
A1 Perez-Cornago, Aurora
A1 Langerak, Anton W
A1 van der Velden, Vincent H J
A1 Vermeulen, Roel
K1 Body Mass Index
K1 Case-Control Studies
K1 Chemokine CXCL13
K1 Cohort Studies
K1 Exercise
K1 Female
AB Sustained B-cell activation is an important mechanism contributing to B-cell lymphoma (BCL). We aimed to validate four previously reported B-cell activation markers predictive of BCL risk (sCD23, sCD27, sCD30, and CXCL13) and to examine their possible mediating effects on the association between anthropometric and lifestyle factors and major BCL subtypes. Pre-diagnostic serum levels were measured for 517 BCL cases and 525 controls in a nested case-control study. The odds ratios of BCL were 6.2 in the highest versus lowest quartile for sCD23, 2.6 for sCD30, 4.2 for sCD27, and 2.6 for CXCL13. Higher levels of all markers were associated with increased risk of chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL). Following mutual adjustment for the other immune markers, sCD23 remained associated with all subtypes and CXCL13 with FL and DLBCL. The associations of sCD23 with CLL and DLBCL and CXCL13 with DLBCL persisted among cases sampled > 9 years before diagnosis. sCD23 showed a good predictive ability (area under the curve = 0.80) for CLL, in particular among older, male participants. sCD23 and CXCL13 showed a mediating effect between body mass index (positive) and DLBCL risk, while CXCL13 contributed to the association between physical activity (inverse) and DLBCL. Our data suggest a role of B-cell activation in BCL development and a mediating role of the immune system for lifestyle factors.
PB Nature Publishing Group
YR 2020
FD 2020-07-04
LK http://hdl.handle.net/10668/16105
UL http://hdl.handle.net/10668/16105
LA en
NO Saberi Hosnijeh F, Kolijn PM, Casabonne D, Nieters A, Solans M, Naudin S, et al. Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development. Sci Rep. 2020 Aug 14;10(1):13814.
NO The authors thank Dr. Marco W.J. Schreurs and the laboratory technicians Cindy Kneppers, Pamela Vasic, and Anneloes van Krimpen who performed the immune marker assays (Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands), Moreover, the authors thank the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, for their contribution and ongoing support to the EPIC Study. European Commission (DG-SANCO), International Agency for Research on Cancer, Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l’Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Grant number: ERC2009-AdG 232997; Grant sponsors: Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); German Federal Ministry of Education and Research (BMBF 01EO1303); Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), (Spain); Spanish Ministry of Economy and Competitiveness—Carlos III Institute of Health cofunded by FEDER funds/European Regional Develpment Fund (ERDF)—a way to build Europe; Grant numbers: PI13/00061 (to Granada), PI13/01162 (to EPIC-Murcia), Regional Governments of Andalucıa, Asturias, Basque Country, Murcia and Navarra), PI17/01280 and PI14/01219 (to Barcelona); Grant sponsor: Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), CERCA Programme/Generalitat de Catalunya for institutional support; Grant number (2017SGR1085); Grant sponsors: Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Vasterbotten (Sweden) and Cancer Research UK; Grant numbers: 14136 (to EPIC-Norfolk), C570/A11692, C570/A16491 and C8221/A19170 (to EPIC-Oxford); Grant sponsor: Medical Research Council; Grant numbers: 1000143 (to EPIC-Norfolk), MR/M012190/1 (to EPIC-Oxford, UK); Erasmus University Rotterdam Fellowship (EUR number: CvB/HP/PR/UB00003201; Fatemeh Saberi Hosnijeh); NOVEL Transcan 2 EU/Dutch Cancer Society grant to Roel Vermeulen and Anton W. Langerak.
DS RISalud
RD Apr 7, 2025